GlassScriptPhysician profile
George Varsos
NPI 1639193345
$1,197.55
in general payments reported to CMS, 2019-2025
18 companies · $531 in 2025
The $531 reported for 2025 was more than what 76% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $116 · 2023: $39.27 · 2024: $511 · 2025: $531.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,081.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,081.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $320.04 | 2022-2025 | Tagrisso, Imfinzi |
| Novartis Pharmaceuticals Corporation | $210.44 | 2024-2025 | |
| Novocure INC. | $197.16 | 2025 | Optune Lua (Novottf-200t), Optune Gio |
| Astellas Pharma US INC | $103.37 | 2024-2025 | Padcev, Vyloy, Xtandi |
| Incyte Corporation | $51.47 | 2024-2025 | Jakafi |
| Janssen Biotech, INC. | $50.43 | 2024 | Rybrevant, Tecvayli, Talvey |
| Eisai INC. | $36.11 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.04 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $27.94 | 2024 | Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $25.06 | 2024 | Fruzaqla |
| Karyopharm Therapeutics INC. | $24.88 | 2024 | Xpovio |
| Genzyme Corporation | $20.03 | 2024 | |
| Myriad Genetic Laboratories, INC. | $17.16 | 2024 | Myrisk |
| Acrotech Biopharma INC. | $17.03 | 2023 | Beleodaq |
| Ipsen Biopharmaceuticals, INC | $16.85 | 2024 | Onivyde |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Springworks Therapeutics, INC. | $16.36 | 2024 | Ogsiveo |
| Recordati_rare_diseases_inc. | $16.09 | 2024 | Sylvant |
| Merck Sharp & Dohme LLC | $16.09 | 2024 | Keytruda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Varsos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.